JP4917893B2 - 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法 - Google Patents

作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法 Download PDF

Info

Publication number
JP4917893B2
JP4917893B2 JP2006543959A JP2006543959A JP4917893B2 JP 4917893 B2 JP4917893 B2 JP 4917893B2 JP 2006543959 A JP2006543959 A JP 2006543959A JP 2006543959 A JP2006543959 A JP 2006543959A JP 4917893 B2 JP4917893 B2 JP 4917893B2
Authority
JP
Japan
Prior art keywords
dosage form
agent
core
sheath
coextrusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006543959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513960A (ja
Inventor
フラス，ロバート，ピー．
マッセリンク，ジョン，ケイ．
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2007513960A publication Critical patent/JP2007513960A/ja
Application granted granted Critical
Publication of JP4917893B2 publication Critical patent/JP4917893B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006543959A 2003-12-09 2004-12-08 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法 Expired - Lifetime JP4917893B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52855003P 2003-12-09 2003-12-09
US60/528,550 2003-12-09
PCT/US2004/041154 WO2005055981A2 (en) 2003-12-09 2004-12-08 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011020960A Division JP5473958B2 (ja) 2003-12-09 2011-02-02 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
JP2011272389A Division JP2012082214A (ja) 2003-12-09 2011-12-13 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法

Publications (2)

Publication Number Publication Date
JP2007513960A JP2007513960A (ja) 2007-05-31
JP4917893B2 true JP4917893B2 (ja) 2012-04-18

Family

ID=34676850

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006543959A Expired - Lifetime JP4917893B2 (ja) 2003-12-09 2004-12-08 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
JP2011020960A Expired - Lifetime JP5473958B2 (ja) 2003-12-09 2011-02-02 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
JP2011272389A Pending JP2012082214A (ja) 2003-12-09 2011-12-13 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011020960A Expired - Lifetime JP5473958B2 (ja) 2003-12-09 2011-02-02 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
JP2011272389A Pending JP2012082214A (ja) 2003-12-09 2011-12-13 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法

Country Status (13)

Country Link
US (1) US20070269505A1 (enExample)
EP (1) EP1691892B1 (enExample)
JP (3) JP4917893B2 (enExample)
AT (1) ATE355103T1 (enExample)
CA (1) CA2548834C (enExample)
CY (1) CY1106600T1 (enExample)
DE (1) DE602004005076T2 (enExample)
DK (1) DK1691892T3 (enExample)
ES (1) ES2281851T3 (enExample)
PL (1) PL1691892T3 (enExample)
PT (1) PT1691892E (enExample)
SI (1) SI1691892T1 (enExample)
WO (1) WO2005055981A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012082214A (ja) * 2003-12-09 2012-04-26 Euro-Celtique Sa 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592609A (zh) * 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1615625A4 (en) 2003-04-21 2010-12-15 Euro Celtique Sa SAFETY DOSING FORM WITH COEXTRUDED PARTICLES OF AN UNWANTED MEDIUM AND METHOD OF MANUFACTURING THEREOF
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PL1729730T3 (pl) 2004-03-30 2009-06-30 Euro Celtique Sa Odporna na zniszczenie postać dawkowania zawierająca adsorbent i środek przeciwdziałający
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
AU2007275581B2 (en) 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2923102C (en) * 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Abuse resistant drugs, method of use and method of making
AU2015200313B2 (en) * 2007-12-17 2016-12-01 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2009079518A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals. Llc Pharmaceutical composition
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
AU2008343267A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
CN102209540A (zh) * 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
BRPI1001091A2 (pt) * 2009-04-22 2011-03-22 Dr Suwelack Skin & Health Care Ag artigo moldado revestido secado por congelamento
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
ITVR20110069A1 (it) * 2011-04-06 2012-10-07 Eurocoating S P A Metodo per la realizzazione di un biomateriale a base di calcio fosfato sotto forma di granuli e/o loro aggregati e biomateriale ottenuto con lo stesso
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
ES2703688T3 (es) * 2011-09-16 2019-03-12 Purdue Pharma Lp Formulaciones de liberación inmediata resistentes a alteración
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2835246A1 (en) * 2013-08-05 2015-02-11 Ansa Termoplastici S.r.l. Method and apparatus for producing extruded plastic elements
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6063405A (en) * 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
IN183097B (enExample) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
DE19812688A1 (de) * 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
AU776666B2 (en) * 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
CN1592609A (zh) * 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
EP1615625A4 (en) * 2003-04-21 2010-12-15 Euro Celtique Sa SAFETY DOSING FORM WITH COEXTRUDED PARTICLES OF AN UNWANTED MEDIUM AND METHOD OF MANUFACTURING THEREOF
US20070269505A1 (en) * 2003-12-09 2007-11-22 Flath Robert P Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012082214A (ja) * 2003-12-09 2012-04-26 Euro-Celtique Sa 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法

Also Published As

Publication number Publication date
WO2005055981A3 (en) 2005-08-11
WO2005055981A2 (en) 2005-06-23
CA2548834C (en) 2009-08-11
US20070269505A1 (en) 2007-11-22
CY1106600T1 (el) 2012-01-25
JP2012082214A (ja) 2012-04-26
JP2007513960A (ja) 2007-05-31
CA2548834A1 (en) 2005-06-23
JP5473958B2 (ja) 2014-04-16
DE602004005076D1 (de) 2007-04-12
DE602004005076T2 (de) 2007-11-15
JP2011126895A (ja) 2011-06-30
EP1691892A2 (en) 2006-08-23
ES2281851T3 (es) 2007-10-01
PL1691892T3 (pl) 2007-07-31
DK1691892T3 (da) 2007-06-25
ATE355103T1 (de) 2006-03-15
EP1691892B1 (en) 2007-02-28
SI1691892T1 (sl) 2007-08-31
PT1691892E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
JP5473958B2 (ja) 作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
JP5501553B2 (ja) 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
US10441547B2 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
KR101053558B1 (ko) 흡착제 및 억제제를 포함하는 내변조성 제형
EP1348429B1 (en) Melt-extruded orally administrable opioid formulations
JP4997109B2 (ja) 用量比例的な定常状態ｃａｖｅおよび定常状態ａｕｃ、ならびに、用量比例よりも小さい単回投与ｃｍａｘを有するオピオイド投薬形態物
MXPA06006154A (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110916

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120127

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150203

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4917893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term